Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.2165/11319940-000000000-00000

Indexing Status
Subject indexing assigned by NLM

MeSH
Adrenergic beta-Antagonists /therapeutic use; Aged; Angiotensin-Converting Enzyme Inhibitors /therapeutic use; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Health Care Costs; Heart Failure /drug therapy /economics /etiology; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists /economics /therapeutic use; Myocardial Infarction /complications /economics; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Regression Analysis; Spironolactone /analogs & derivatives /economics /therapeutic use

AccessionNumber
22010000935

Date bibliographic record published
10/11/2010